228 related articles for article (PubMed ID: 27305776)
21. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
22. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
23. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.
Hatton OL; Harris-Arnold A; Schaffert S; Krams SM; Martinez OM
Immunol Res; 2014 May; 58(2-3):268-76. PubMed ID: 24619311
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.
Savard M; Gosselin J
Virus Res; 2006 Aug; 119(2):134-45. PubMed ID: 16545476
[TBL] [Abstract][Full Text] [Related]
25. Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion.
van Gent M; Gram AM; Boer IGJ; Geerdink RJ; Lindenbergh MFS; Lebbink RJ; Wiertz EJ; Ressing ME
J Gen Virol; 2015 Apr; 96(Pt 4):858-865. PubMed ID: 25502648
[TBL] [Abstract][Full Text] [Related]
26. Nonhuman primate models for Epstein-Barr virus infection.
Wang F
Curr Opin Virol; 2013 Jun; 3(3):233-7. PubMed ID: 23562212
[TBL] [Abstract][Full Text] [Related]
27. Immunity and Immune Evasion Mechanisms of Epstein-Barr Virus.
Yao Y; Kong W; Yang L; Ding Y; Cui H
Viral Immunol; 2023 Jun; 36(5):303-317. PubMed ID: 37285188
[TBL] [Abstract][Full Text] [Related]
28. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
Wingate PJ; McAulay KA; Anthony IC; Crawford DH
J Med Virol; 2009 May; 81(5):870-7. PubMed ID: 19319950
[TBL] [Abstract][Full Text] [Related]
30. TRIM29 promotes DNA virus infections by inhibiting innate immune response.
Xing J; Zhang A; Zhang H; Wang J; Li XC; Zeng MS; Zhang Z
Nat Commun; 2017 Oct; 8(1):945. PubMed ID: 29038422
[TBL] [Abstract][Full Text] [Related]
31. Innate immune responses against Epstein Barr virus infection.
Chijioke O; Azzi T; Nadal D; Münz C
J Leukoc Biol; 2013 Dec; 94(6):1185-90. PubMed ID: 23812328
[TBL] [Abstract][Full Text] [Related]
32. Primary Epstein-Barr virus infection.
Dunmire SK; Verghese PS; Balfour HH
J Clin Virol; 2018 May; 102():84-92. PubMed ID: 29525635
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
[TBL] [Abstract][Full Text] [Related]
34. [History of resaerch on Epstein-Barr virus--target cells of infection, and disease].
Ohga S
Uirusu; 2014; 64(1):67-74. PubMed ID: 25765982
[TBL] [Abstract][Full Text] [Related]
35. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.
Djaoud Z; Guethlein LA; Horowitz A; Azzi T; Nemat-Gorgani N; Olive D; Nadal D; Norman PJ; Münz C; Parham P
J Exp Med; 2017 Jun; 214(6):1827-1841. PubMed ID: 28468758
[TBL] [Abstract][Full Text] [Related]
36. An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.
Ohashi M; Fogg MH; Orlova N; Quink C; Wang F
PLoS Pathog; 2012 Dec; 8(12):e1003095. PubMed ID: 23300447
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-encoded dUTPase modulates immune function and induces sickness behavior in mice.
Padgett DA; Hotchkiss AK; Pyter LM; Nelson RJ; Yang E; Yeh PE; Litsky M; Williams M; Glaser R
J Med Virol; 2004 Nov; 74(3):442-8. PubMed ID: 15368518
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
39. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
40. Tree Shrew Is a Suitable Animal Model for the Study of Epstein Barr Virus.
Xia W; Chen H; Feng Y; Shi N; Huang Z; Feng Q; Jiang X; He G; Xie M; Lai Y; Wang Z; Yi X; Tang A
Front Immunol; 2021; 12():789604. PubMed ID: 35111158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
